| Citation: | Lyu Rixin, Fan Hua. Application of calcineurin inhibitor guided by CYP3A5 genotypes after liver transplantation[J]. ORGAN TRANSPLANTATION, 2019, 10(3): 283-287. doi: 10.3969/j.issn.1674-7445.2019.03.010
|
| [1] |
FANG Y, GAO J, WANG T, et al. Intraindividual variation and correlation of cytochrome P450 activities in human liver microsomes[J]. Mol Pharm, 2018, 15(11):5312-5318. DOI: 10.1021/acs.molpharmaceut.8b00787.
|
| [2] |
LIAO JH, LI CC, WU SH, et al. Gene variations of sixth complement component affecting tacrolimus metabolism in patients with liver transplantation for hepatocellular carcinoma[J]. Chin Med J (Engl), 2017, 130(14):1670-1676. DOI: 10.4103/0366-6999.209886.
|
| [3] |
REN L, TENG M, ZHANG T, et al. Donors FMO3 polymorphisms affect tacrolimus elimination in Chinese liver transplant patients[J]. Pharmacogenomics, 2017, 18(3):265-275. DOI: 10.2217/pgs-2016-0098.
|
| [4] |
CZERWIŃSKI M, AMUNOM I, PIRYATINSKY V, et al. Direct and cytokine-mediated effects of albumin-fused growth hormone, TV-1106, on CYP enzyme expression in human hepatocytes in vitro[J]. Pharmacol Res Perspect, 2018, 6(3):e00397. DOI: 10.1002/prp2.397.
|
| [5] |
PASTERNAK AL, ZHANG L, HERTZ DL. CYP3A pharmacogenetic association with tacrolimus pharmacokinetics differs based on route of drug administration[J]. Pharmacogenomics, 2018, 19(6):563-576. DOI: 10.2217/pgs-2018-0003.
|
| [6] |
HENDERSON LM, CLAW KG, WOODAHL EL, et al. P450 pharmacogenetics in Indigenous North American populations[J]. J Pers Med, 2018, 8(1): E9. DOI: 10.3390/jpm8010009.
|
| [7] |
LIN G, ZHANG X, ZHANG K, et al. Evaluation of tacrolimus-related CYP3A5 genotyping in China: results from the first external quality assessment exercise[J]. J Clin Lab Anal, 2018, 32(8):e22563. DOI: 10.1002/jcla.22563.
|
| [8] |
KANEKO T, ARAI M, WATANABE A, et al. Effectiveness of measuring genetic polymorphisms in metabolizing enzymes of tacrolimus within one medical facility[J]. J Nippon Med Sch, 2017, 84(6):274-279. DOI: 10.1272/jnms.84.274.
|
| [9] |
LIU J, OUYANG Y, CHEN D, et al. Donor and recipient P450 gene polymorphisms influence individual pharmacological effects of tacrolimus in Chinese liver transplantation patients[J]. Int Immunopharmacol, 2018, 57:18-24. DOI: 10.1016/j.intimp.2018.02.005.
|
| [10] |
DENG R, LIAO Y, LI Y, et al. Association of CYP3A5, CYP2C8, and ABCB1 polymorphisms with early renal injury in Chinese liver transplant recipients receiving tacrolimus[J]. Transplant Proc, 2018, 50(10):3258-3265. DOI: 10.1016/j.transproceed.2018.06.040.
|
| [11] |
KUYPERS DR. " What do we know about tacrolimus pharmacogenetics in transplant recipients?" [J]. Pharmacogenomics, 2018, 19(7):593-597. DOI: 10.2217/pgs-2018-0035.
|
| [12] |
JI E, KIM MG, OH JM. CYP3A5 genotype-based model to predict tacrolimus dosage in the early postoperative period after living donor liver transplantation[J]. Ther Clin Risk Manag, 2018, 14:2119-2126. DOI: 10.2147/TCRM.S184376.
|
| [13] |
MIN S, PAPAZ T, LAFRENIERE-ROULA M, et al.A randomized clinical trial of age and genotype-guided tacrolimus dosing after pediatric solidorgan transplantation[J]. Pediatr Transplant, 2018, 22(7):e13285. DOI: 10.1111/petr.13285.
|
| [14] |
MOES DJ, VAN DER BENT SA, SWEN JJ, et al. Population pharmacokinetics and pharmacogenetics of once daily tacrolimus formulation in stable liver transplant recipients[J]. Eur J Clin Pharmacol, 2016, 72(2):163-174. DOI: 10.1007/s00228-015-1963-3.
|
| [15] |
HENDIJANI F, AZARPIRA N, KAVIANI M. Effect of CYP3A5*1 expression on tacrolimus required dose after liver transplantation: a systematic review and Meta-analysis[J]. Clin Transplant, 2018, 32(8):e13306. DOI: 10.1111/ctr.13306.
|
| [16] |
KATO H, USUI M, MURAKI Y, et al. Intravenous administration of tacrolimus stabilizes control of blood concentration regardless of CYP3A5 polymorphism in living donor liver transplantation: comparison of intravenous infusion and oral administration in early postoperative period[J]. Transplant Proc, 2018, 50(9):2684-2689. DOI: 10.1016/j.transproceed.2018.03.049.
|
| [17] |
OU B, LIU Y, ZHANG T, et al. TLR9 rs352139 genetic variant promotes tacrolimus elimination in Chinese liver transplant patients during the early posttransplantation period[J]. Pharmacotherapy, 2019, 39(1):67-76. DOI: 10.1002/phar.2204.
|
| [18] |
LIU Y, ZHANG T, ZHANG X, et al. A new donors' CYP3A5 and recipients' CYP3A4 cluster predicting tacrolimus disposition, and new-onset hypertension in Chinese liver transplant patients[J]. Oncotarget, 2017, 8(41):70250-70261. DOI: 10.18632/oncotarget.19606.
|
| [19] |
BOERNER BP, SHIVASWAMY V, WOLATZ E, et al. Post-transplant diabetes: diagnosis and management[J]. Minerva Endocrinol, 2018, 43(2):198-211. DOI: 10.23736/S0391-1977.17.02753-5.
|
| [20] |
RIVA N, DIP M, HALAC E, et al. Survival time to biopsy-proven acute rejection and tacrolimus adverse drug reactions in pediatric liver transplantation[J]. Ther Drug Monit, 2018, 40(4):401-410. DOI: 10.1097/FTD.0000000000000517.
|
| [21] |
MURAKI Y, MIZUNO S, NAKATANI K, et al. Monitoring of peripheral blood cluster of differentiation 4+ adenosine triphosphate activity and CYP3A5 genotype to determine the pharmacokinetics, clinical effects and complications of tacrolimus in patients with autoimmune diseases[J]. Exp Ther Med, 2018, 15(1):532-538. DOI: 10.3892/etm.2017.5364.
|
| [22] |
HEITS N, KESEROVIC D, MUND N, et al. Cognitive evaluation in liver transplant patients under calcineurin inhibitor maintenance therapy[J]. Transplant Direct, 2017, 3(4):e146. DOI: 10.1097/TXD.0000000000000658.
|
| [23] |
ZHANG X, LIN G, TAN L, et al. Current progress of tacrolimus dosing in solid organ transplant recipients: pharmacogenetic considerations[J]. Biomed Pharmacother, 2018, 102:107-114. DOI: 10.1016/j.biopha.2018.03.054.
|
| [24] |
CAMPAGNE O, MAGER DE, TORNATORE KM. Population pharmacokinetics of tacrolimus in transplant recipients: what did we learn about sources of interindividual variabilities?[J]. J Clin Pharmacol, 2019, 59(3):309-325. DOI: 10.1002/jcph.1325.
|
WeChat Subscription Account
Wechat Service Account
Supported by:
Beijing Renhe Information Technology Co. Ltd
DownLoad: